Literature DB >> 8763611

Lack of production of the 19-kDa glycolipoprotein in certain strains of Mycobacterium tuberculosis.

R Lathigra1, Y Zhang, M Hill, M J Garcia, P S Jackett, J Ivanyi.   

Abstract

The 19-kDa glycolipoprotein of Mycobacterium tuberculosis (PT19) is a prominent antigen recognized by both T cells and antibodies from tuberculosis patients. We report here that two strains, I2646 and S1, when grown either in bacteriological culture or during infection of mice, do not produce this constituent, as judged by ELISA and Western blot assays. Southern blot analysis of the chromosomal DNA showed that both strains displayed the restriction fragment as in H37Rv DNA, suggesting the lack of gross gene alterations. Sequence analysis revealed multiple microlesions including small deletions, point mutations and nucleotide insertions, leading to either premature termination or alteration of open reading frame in both strains. Transformation of both mutant strains with the wild-type gene on a multicopy plasmid resulted in overproduction of native PT19. Infection of mice suggested that the I2646 is of low virulence and that the transformant-producing native PT19 exhibited higher virulence, as assessed by viable counts and gross lesions in the infected organs. The mechanisms and significance of the lack of PT19 production in certain M. tuberculosis strains is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763611     DOI: 10.1016/0923-2508(96)81384-2

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  12 in total

1.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

2.  Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle.

Authors:  H M Vordermeier; A Whelan; P J Cockle; L Farrant; N Palmer; R G Hewinson
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 3.  Virulence factors of the Mycobacterium tuberculosis complex.

Authors:  Marina A Forrellad; Laura I Klepp; Andrea Gioffré; Julia Sabio y García; Hector R Morbidoni; María de la Paz Santangelo; Angel A Cataldi; Fabiana Bigi
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

4.  Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection.

Authors:  X Zhu; N Venkataprasad; J Ivanyi; H M Vordermeier
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

5.  Negligible genetic diversity of mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure.

Authors:  J M Musser; A Amin; S Ramaswamy
Journal:  Genetics       Date:  2000-05       Impact factor: 4.562

6.  Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle.

Authors:  H M Vordermeier; P C Cockle; A Whelan; S Rhodes; N Palmer; D Bakker; R G Hewinson
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

7.  Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced cytokine production by human macrophages in vitro.

Authors:  F A Post; C Manca; O Neyrolles; B Ryffel; D B Young; G Kaplan
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Antigen specificity in experimental bovine tuberculosis.

Authors:  S G Rhodes; D Gavier-Widen; B M Buddle; A O Whelan; M Singh; R G Hewinson; H M Vordermeier
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 9.  Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence.

Authors:  Issar Smith
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.

Authors:  Adam J Gehring; Roxana E Rojas; David H Canaday; David L Lakey; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.